Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07190209 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 942
- Enrollment target
- 20
- Study locations
NCT07190209: Recruiting Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by Sanofi.
NCT07190209 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by Sanofi. The registered enrollment target is 942 participants, below the 1,743-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07190209, a Phase 3 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 942 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
Primary Outcome
The annualized moderate or severe COPD exacerbation rate up to 48 weeks treatment period compared to placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lunsekimig
Study Locations (20)
Florida
- Helix Biomedics- Site Number : 8400065 - Boynton Beach
- Beautiful Minds Clinical Research Center- Site Number : 8400017 - Cutler Bay
- Eastern Medical Group Research- Site Number : 8400020 - Fort Myers
- Premier Medical Associates- Site Number : 8400012 - Lady Lake
- MCR Research- Site Number : 8400004 - Miami
- Nuren Medical & Research Center- Site Number : 8400030 - Miami
- Deluxe Health Center- Site Number : 8400010 - Miami Lakes
- Omega Research Consultants - Orlando - Forest City- Site Number : 8400015 - Orlando
- Broward Research Center - Pembroke Pines- Site Number : 8400053 - Pembroke Pines
- Clinical Research Trials of Florida- Site Number : 8400011 - Tampa
- Deluxe Health Center-Tampa- Site Number : 8400056 - Tampa
California
- IMAX Clinical Trials- Site Number : 8400109 - La Palma
- Long Beach Research Institute- Site Number : 8400027 - Long Beach
- Downtown L.A. Research Center- Site Number : 8400009 - Los Angeles
- Newport Native MD- Site Number : 8400003 - Newport Beach
- Paradigm Research - Redding- Site Number : 8400108 - Redding
- Amicis Research Center - Valencia- Site Number : 8400119 - Valencia
Arizona
- Chandler Clinical Research Trials- Site Number : 8400025 - Chandler
- Pulmonary Associates - Phoenix - East Bell Road- Site Number : 8400114 - Phoenix
- Epic Medical Research - Surprise- Site Number : 8400096 - Surprise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2030-01-22 |
| Phase | Phase 3 |
What NCT07190209 shows while recruiting
NCT07190209 is an interventional study that assigns participants to a tested intervention. The registered 942 participants enrollment target is mid-sized for trials with a published cap, below the 1,743-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07190209 names 20 study sites across 3 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07190209 about?
NCT07190209 is a clinical study titled "Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype". This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD...
What is the current status of trial NCT07190209?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 942 participants. The study started on 2025-09-16. Estimated completion is 2030-01-22.
What conditions does trial NCT07190209 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07190209?
The interventions under investigation include: Placebo (DRUG), Lunsekimig (DRUG).
Who is sponsoring clinical trial NCT07190209?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07190209 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07190209's enrollment target sits among peer trials
942 13th of 86 higher than 73 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
-
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI